Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement R4 신재령 / Prof. 김시영 Annals of Oncology 23: 2997–3006,

Slides:



Advertisements
Similar presentations
TOP2A IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN UNSELECTED BREAST CANCER Amit Pancholi Molecular Profiling of Breast Cancer: Predictive Markers of Long.
Advertisements

CD10, scored as positive versus negative all path 1 path 2 path 3 path 4 path 5 path 6 path 7 path 8 path 9 CD10 can be reproducibly scored, but is very.
Oncologic Drugs Advisory Committee
Implicaciones clínicas de los subtipos intrínsecos de cáncer de mama
Breast Cancer Systemic Therapy for Early Stage Disease
Clinical Trial Designs for the Evaluation of Prognostic & Predictive Classifiers Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer.
Carolina Breast Cancer Study: Breast cancer subtypes and race Robert Millikan University of North Carolina Chapel Hill, NC.
Is mammacarcinoom onder de veertig jaar morfologisch en genetisch een andere ziekte? Marc van de Vijver, Netherlands Cancer Institute, Amsterdam, NL.
The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)
Current state of breast cancer classification Marcella Mottolese UOC Anatomia Patologica.
Expression profiles for prognosis and prediction Laura J. Van ‘t Veer The Netherlands Cancer Institute, Amsterdam.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Predictors of HER2 FISH amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis Maria Vittoria Dieci 1,
MammaPrint, the story of the 70-gene profile
Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005) 1 Concordance of HER2 Central Assessment.
References 1.Salazar R, Roepman P, Capella G et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J.
Understanding and Treating Triple-Negative Breast Cancer Elshami M. Elamin, MD Medical Oncologist Central Care Cancer Center Wichita,
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology.
Metastatic Breast Cancer: One Size Does Not Fit All Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service MSKCC.
1 The Role of the Oncotype DX ® Breast Cancer Assay in the Neoadjuvant Setting.
About these slides SPEC – Short Presentation in Emerging Concepts Provided by the CAP as an aid to pathologists to facilitate discussion on the topic.
Can we use multigene-tests to guide the adjuvant treatment of early breast cancer? R5 陳三奇 VS 趙大中 J Natl Compr Canc Netw 2013;11: J.
These slides were released by the speaker for internal use by Novartis.
Wildiers H, et al. Lancet Oncol. 2007;8:1101. Breast Cancer in Elderly (>65 Years) Recommendations of the International Society of Geriatric Oncology Surgical.
The 70 gene Mammaprint ™ signature: a comparison with traditional clinico-pathological parameters. Patrizia Querzoli 1, Massimo Pedriali 1, Gardenia Munerato.
A 14-gene prognosis signature predicts metastasis risk in node-negative, estrogen receptor-positive, Tamoxifen-treated breast cancer in different ethnogeographic.
Appendix Supplementary data (online only) to: Marleen Kok, Wilbert Zwart, Caroline Holm, Renske Fles, Michael Hauptmann, Laura J. Van ’t Veer, Lodewyk.
Enabling biomarker validation in breast cancer molecular subtypes: sensitivity and specificity of array-based subtype classification in 983 patients Balázs.
Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.
Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.
Dubsky P et al. Proc SABCS 2012;Abstract S4-3.
TREATMENT Mastectomy -traditionally, treatment of breast ca has been surgical -19 century, surgical treatment : local excision ~ total mastectomy : radical.
Michael Birrer Ian McNeish New Developments in Biology and Targets of Epithelial Ovarian Cancer.
Guanylyl Cyclase C (GCC) Lymph Nodes (LN) Classification as a Prognostic Marker in Patients with Stage II Colon Cancer: A Pooled Analysis Daniel J. Sargent,
HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF.
St. Gallen 2007 Consensusmeeting P. Berteloot. First select the target : better choice of adjuvant treatments for breast cancer patients St Gallen 2005.
Breast cancer in elderly patients (70 years and older): The University of Tennessee Medical Center at Knoxville 10 year experience Curzon M, Curzon C,
Neoadjuvant SystemicTreatment Strategies for Breast Cancer Donald W. Northfelt, MD, FACP Professor of Medicine Mayo Clinic College of Medicine Associate.
Snyder D, Heidel RE, Panella T, Bell J, Orucevic A University of Tennessee Medical Center – Knoxville Departments of Pathology, Surgery, and Medicine BREAST.
Effect of 21-Gene Reverse- Transcriptase Polymerase Chain Reaction Assay on Treatment Recommendations in Patients with Lymph Node-Positive and Estrogen.
Prognostic Value of Genomic Analysis After Neoadjuvant Chemotherapy for Breast Cancer Mayer EL et al. Proc SABCS 2010;Abstract P
Use of Oncotype Dx® Testing Breast SSG meeting 10 th July 2015 Dr Rebecca Bowen.
Postmenopausal breast cancer patients included in the original Stockholm tamoxifen trial (n=2459) Stockholm 2 cohort (n=679) Stockholm 3 cohort (n=1780)
High risk premenopausal Luminal A breast cancer patients derive no benefit from adjuvant chemotherapy: results from DBCG77B randomized trial 1 San Antonio.
Scott Kopetz, MD, PhD Department of Gastrointestinal Medical Oncology
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
A B C Supplementary Figure S1. Time-dependent assessment of grade, GGI and PAM50 in untreated patients Landmark analyses of the Kaplan-Meier estimates.
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann Journal.
Annals of Oncology 24: 2206–2223, 2013 R3 조영학
R3 정수웅 / Prof. 김시영 This article was published on September 28, 2015, at NEJM.org. DOI: /NEJMoa Prospective Validation of a 21-Gene Expression.
Annals of Oncology 23: 298–304, 2012 종양혈액내과 R4 김태영 / prof. 김시영.
Management of the axilla in early breast cancer patients in the genomic era M. Oliveira, J. Cortés, M. Bellet, J. Balmaña, L. De Mattos-Arruda, P. Gómez,
How Do We Treat HR positive Breast Cancer in Postmenopausal Women?
Patterns of care and comparative effectiveness of endocrine therapy for premenopausal women with early breast cancer A multi-institution cohort study February.
Case 6 A 49 year old female was found to have a 1.3 cm spiculated mass on screening mammogram Ultrasound revealed a 1.2 cm hypoechoic mass with posterior.
Estrogen-Regulated Genes Predict Survival in Hormone Receptor–Positive Breast Cancers J Clin Oncol 24: Daniel S. Oh, Melissa A. Troester,
Table S1: The results of ER, PgR, and HER2 status in IHC testing and mRNA expression in the full Consortium population (N=389) HER2 statusER status PgR.
The New trends in the Management of Breast Cancer 謝渙發 桃園縣醫師公會監事 怡仁綜合醫院副院長 教育部部定助理教授 國防醫學院外科學系臨床教授.
Mamounas EP et al. Proc SABCS 2012;Abstract S1-10.
Update in Treatment of Early Breast Cancer
Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer.
THBT neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer woman Antonino Grassadonia Università «G. D’Annunzio» – Chieti-Pescara.
IOV – Istituto Oncologico Veneto I.R.C.C.S.
Hallett, et al., - Supplementary Figure 1
High-level TNFSF13 predict a good response to post-operative chemotherapy in patients with basal-like breast cancer: A systematic review 林惠鈺1,2 歸家豪1,3.
徐慧萍1 羅竹君1,2 郭耀隆1 李國鼎1 國立成功大學醫學院附設醫院外科部1 國立成功大學醫學院臨床醫學研究所2
A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer  Gen Wang, Xiaosong.
Transcriptional Signature of Histone Deacetylases in Breast cancer
Effect of Obesity on Prognosis after Early Breast Cancer
Presentation transcript:

Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement R4 신재령 / Prof. 김시영 Annals of Oncology 23: 2997–3006, 2012 S. Guiu1, S. Michiels, F. André, J. Cortes, C. Denkert, A. Di Leo, B. T. Hennessy, T. Sorlie, C. Sotiriou, N. Turner, M. Van de Vijver, G. Viale, S. Loi& J. S. Reis-Filho

Introduction The classical breast cancer classification systems were solely based on the histological appearances of breast cancers The current stratification of breast cancers into clinically meaningful subgroups is based on prognostic clinicopathological parameters other that type, including histological grade, presence of lymph node metastasis and lympho-vascular invasion Predictive biomarkers, such as expression of ER, PR, and the assessment of HER2 status, have proven to be clinically useful

Microarray-based gene expression studies - breast cancer comprises a heterogeneous group of diseases that have different distinct molecular features. Perou et al, initially identified four breast cancer ‘intrinsic’ subtypes (basal-like, HER2-enriched, luminal and normal breast-like), which were shown to display gene expression patterns. Additional class discovery studies with larger datasets resulted in the identification of additional molecular subtypes, including interferon-rich, claudin-low and molecular apocrine

Methods for the identification of the molecular subtypes of breast cancer (that is, single sample predictors) Prediction analysis of microarray (PAM50) - quantitative real-time PCR (qRT-PCR) - RNA extracted from formalin-fixed paraffin-embedded(FFPE) samples An assay in development by NanoString Technologies, based on the PAM50 gene expression signature, provides a subtype classification as well as a prognostic score (referred to as the ROR-S) that predicts the probability of cancer recurrence over 10 years This PAM50 Breast Cancer Intrinsic Classifier™ is currently commercially available from ARUP laboratories

The cost, complexity and initial requirement of fresh frozen tissues for GEP have limited its use in clinical practice and led to the development of immuno-histochemical (IHC) surrogate definitions for the identification of the molecular subtypes of breast cancer

Methods molecular subtypes The IHC definition of molecular subtypes is based on the St Gallen Consensus 2011 On February 2012, Searched in the MEDLINE database using the terms summarised in Table 2

Evaluation method and procedure The working group adopted a Delphi process which was coordinated by a medical oncology doctorate scholar. The Delphi process is a structured communication technique; joining an expert panel to answer to a pre-defined question To assess the quality of the studies, evaluation was carried out based on the general principles of the Evaluation of Genomic Applications in Practice and Prevention (EGAPP)

Results A nalytical validity 11 with distinction between luminal A/B based on Ki-67 and only 8 with a cut-off of 14% PAM50 with only two studies using the PAM50 NanoString test

Results

Among 144 patients with luminal A (n = 84) or B (n = 60) tumours (PAM50) and ER+/HER2− (IHC), Cheang et al. determined a Ki-67 cut-off of 14% to distinguish luminal A and B tumors with a sensitivity of 72% and a specificity of 77% J Natl Cancer Inst 2009; 101: 736–750. PAM50 - Parker et al. applied an expanded ‘intrinsic’ gene set of 1900 common genes in four previous studies to the study of 122 breast cancers, and developed a 50-gene subtype predictor (minimised gene set using the qRT-PCR data for genes that passed FFPE performance criteria)

PAM50 had low prediction strength of 0.59, 0.36 and 0.25 for 3, 4 and 5 subtypes, Respectively J Natl Cancer Inst 2011; 104: 311–325. Elloumi et al. highlighted that genomic classification by PAM50 could be altered by normal tissue contamination (typically 30%– 50% in samples) and caused misclassification of a given tumour BMC Med Genomics 2011; 4: 54. Limited information is available on the analytic validity of the PAM50 NanoString test. Nielsen et al. reported a failure rate of 21% in a large retrospective study involving 991 patients, which was mainly due to RNA of suboptimal quality. Clin Cancer Res 2012; 18: 2402–2412.

Results Clinical validity/utility

Clinical validity/utility IHC classification Cheang et al. tested his 14% Ki-67 cut-off in a retrospective analysis of an independent population of 2598 HR+ patients with different adjuvant modalities (no treatment, tamoxifen alone, tamoxifen and chemotherapy with anthracyclines or CMF) J Natl Cancer Inst 2009; 101: 736–750. Luminal B (33%) and luminal-HER2-positive (8%) breast cancers were statistically significantly associated with poor 10-years recurrence-free and disease-specific survival in all adjuvant systemic treatment categories, and similar results were seen in lymph node- positive or lymph node-negative patients treated with tamoxifen alone

Clinical validity/utility IHC classification A retrospective study of 1006 non-consecutive Korean patients, including 53% luminal A and 22% luminal B tumours, reported a significantly better 5-year disease-free and OS for patients with luminal A cancers as compared with those with luminal B disease. Breast 2011; 21: 50–57. Risks of local and regional relapse was significantly higher in patients with HER2, basal-like and luminal B tumours than in those with luminal A breast cancers after mastectomy (n = 2085 patients). J Clin Oncol 2010; 28: 1684–1691. After breast conserving surgery and adjuvant radiotherapy, risk of regional recurrence was only higher in patients with HER2 and basal-like disease on a multivariate survival analysis

Clinical validity/utility PAM50 Both lymph node-positive (65%) and negative ER+ breast cancers from patients uniformly treated with only adjuvant tamoxifen Luminal A breast cancers assigned by the PAM50 assay had significantly better 5 and 10-years disease-specific survival than luminal B, HER2- enriched or basal-like breast cancers. Clin Cancer Res 2010; 16: 5222–5232. Retrospectively samples of 476 of 716 pre-menopausal patients with node- positive breast cancer who were randomised between anthracycline (CEF) versus non-anthracycline (CMF) adjuvant chemotherapy in the NCIC.CTG MA.5 trial A benefit in relapse-free survival and OS with anthracycline regimen was seen only for HER2-enriched tumours Clin Cancer Res 2012; 18: 2402–2412.

IMPAKT 2012 Working Group Statement

The panel concluded that breast cancer classification into molecular subtypes based on the IHC assessment of ER, HER2 and Ki67 with a 14% cut-off and on the PAM50 test does not provide sufficiently robust information to modify systemic treatment decisions The panel does not support the use of PAM50 for current clinical decisions in regards to systemic therapy, especially in cases of discordance with IHC. For example, a HER2-enriched tumour that is not HER2 positive by IHC or FISH should be managed as HER2 negative, as there is no evidence that these patients would benefit from anti-HER2 therapies.

IMPAKT 2012 Working Group Statement Luminal B breast cancers are often described as having a poorer outcome than those with luminal A tumours The panel does not support the notion that luminal A and B should be used to inform clinical decision in regards to the use of adjuvant chemotherapy due to the absence of convincing data on clinical utility both in lymph node-positive or -negative disease (for Ki67 and PAM50)

Conclusions and future directions Currently, clinical variables including tumour size, nodal status, histological grade, ER, PR and HER2 status remain the current ‘gold standard’ for systemic therapy decision making Further studies addressing the clinical utility of the IHC and PAM50 classification and investigating the optimal therapy for patients with discrepant results are warranted. Additional molecular subtypes - Claudin-low and molecular apocrine subtypes Triple-negative breast cancers - two basal-like, immunomodulatory, mesenchymal, mesenchymal stem-like and a luminal androgen receptor subtypes